The Conversation (0)
Viemed Healthcare, Inc. (the "Company" or "Viemed") (NASDAQ:VMD and TSX: VMD.TO), a national leader in respiratory care and technology-enabled home medical equipment services, today announced its financial results for the three months ended March 31, 2023.
Operational highlights (all dollar amounts are USD):
- Net revenues attributable to the Company's core business for the quarter ended March 31, 2023 were $39.6 million, a new Company record, and an increase of $9.4 million, or 31%, over the quarter ended March 31, 2022. Net revenues for the quarter ended March 31, 2023 were up approximately 6% over the quarter ended December 31, 2022.
- Net income for the quarter ended March 31, 2023 totaled $1.5 million. Adjusted EBITDA for the quarter ended March 31, 2023 totaled $8.3 million, a 15% increase as compared to the quarter ended March 31, 2022 which benefited from COVID-19 related revenue and Provider Relief Fund income. A reconciliation of reported non-GAAP financial measures to their most directly comparable U.S. GAAP financial measures can be found in the tables accompanying this press release.
- The Company increased its cash balance by approximately 39% to $23.5 million at March 31, 2023 compared to $16.9 million at December 31, 2022, and increased its overall working capital balance to $23.3 million at March 31, 2023 compared to $20.9 million at December 31, 2022. The Company had no long term debt outstanding as of March 31, 2023.
- The Company recently announced that it has entered into a definitive agreement to acquire Tennessee based Home Medical Products, Inc. ("HMP"), a large regional provider of respiratory focused home medical solutions, which generated annual net revenues of approximately $28 million in 2022.
- The Company expects to generate net revenues attributable to its core business of approximately $40.2 million to $41.2 million during the second quarter of 2023, excluding the impact from any acquired revenues during the period.
"Our recently announced operating results demonstrate that the core business is firing on all cylinders," said Casey Hoyt, Viemed's CEO. "We are excited to amplify our robust organic growth through accretive acquisitions that create powerful revenue synergies, diversify our offerings, and build upon strong relationships with stakeholders. Our recent acquisition initiatives are the natural progression of strategic investments that create a better experience for patients, physicians, and payors, and will ultimately allow us to expand care to those in need."
Conference Call Details
The Company will host a conference call to discuss first quarter results on Tuesday, May 9, 2023 at 11:00 a.m. ET.
Interested parties may participate in the call by dialing:
877-407-6176 (US Toll-Free)
201-689-8451 (International)
Live Audio Webcast: https://event.choruscall.com/mediaframe/webcast.html?webcastid=Zob0C97p
Following the conclusion of the call, an audio recording and transcript of the call can be accessed on the Company's website.
ABOUT Viemed Healthcare, INC.
Viemed is a provider of in-home medical equipment and post-acute respiratory healthcare services in the United States. Viemed's service offerings are focused on effective in-home treatment with clinical practitioners providing therapy and counseling to patients in their homes using cutting edge technology. Visit our website at www.viemed.com.
For further information, please contact:
Glen Akselrod
Bristol Capital
905-326-1888
glen@bristolir.com
Todd Zehnder
Chief Operating Officer
Viemed Healthcare, Inc.
337-504-3802
investorinfo@viemed.com
Forward-Looking Statements
Certain statements contained in this press release may constitute "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 or "forward-looking information" as such term is defined in applicable Canadian securities legislation (collectively, "forward-looking statements"). Often, but not always, forward-looking statements can be identified by the use of words such as "plans", "expects", "is expected", "budget", "potential", "scheduled", "estimates", "forecasts", "intends", "anticipates", "believes", or "projects", or the negatives thereof or variations of such words and phrases or statements that certain actions, events or results "will", "should", "may", "could", "would", "might" or "will be taken", "occur" or "be achieved" or the negative of these terms or comparable terminology. All statements other than statements of historical fact, including those that express, or involve discussions as to, expectations, beliefs, plans, objectives, assumptions or future events or performance, including the Company's net revenue guidance for the second quarter, are not historical facts and may be forward-looking statements and may involve estimates, assumptions and uncertainties that could cause actual results or outcomes to differ materially from those expressed in the forward-looking statements. Such statements reflect the Company's current views and intentions with respect to future events, and current information available to the Company, and are subject to certain risks, uncertainties and assumptions. Many factors could cause the actual results, performance or achievements that may be expressed or implied by such forward-looking statements to vary from those described herein should one or more of these risks or uncertainties materialize. These factors include, without limitation: the general business, market and economic conditions in the regions in which the Company operates; the impact of the COVID-19 pandemic and the actions taken by governmental authorities, individuals and companies in response to the pandemic on our business, financial condition and results of operations, including on the Company's patient base, revenues, employees, and equipment and supplies; significant capital requirements and operating risks that the Company may be subject to; the ability of the Company to implement business strategies and pursue business opportunities; volatility in the market price of the Company's common shares; the Company's novel business model; the state of the capital markets; the availability of funds and resources to pursue operations; reductions in reimbursement rates and audits of reimbursement claims by various governmental and private payor entities; dependence on few payors; possible new drug discoveries; dependence on key suppliers; granting of permits and licenses in a highly regulated business; competition; disruptions in or attacks (including cyber-attacks) on the Company's information technology, internet, network access or other voice or data communications systems or services; the evolution of various types of fraud or other criminal behavior to which the Company is exposed; difficulty integrating newly acquired businesses; the impact of new and changes to, or application of, current laws and regulations; the overall difficult litigation and regulatory environment; increased competition; increased funding costs and market volatility due to market illiquidity and competition for funding; critical accounting estimates and changes to accounting standards, policies, and methods used by the Company; the Company's status as an emerging growth company and a smaller reporting company; and the occurrence of natural and unnatural catastrophic events or health epidemics or concerns, such as the COVID-19 pandemic, and claims resulting from such events or concerns; as well as those risk factors discussed or referred to in the Company's disclosure documents filed with the U.S. Securities and Exchange Commission (the "SEC") available on the SEC's website at www.sec.gov, including the Company's most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q, and with the securities regulatory authorities in certain provinces of Canada available at www.sedar.com . Should any factor affect the Company in an unexpected manner, or should assumptions underlying the forward-looking statements prove incorrect, the actual results or events may differ materially from the results or events predicted. Any such forward-looking statements are expressly qualified in their entirety by this cautionary statement. Moreover, the Company does not assume responsibility for the accuracy or completeness of such forward-looking statements. The forward-looking statements included in this press release are made as of the date of this press release and the Company undertakes no obligation to publicly update or revise any forward-looking statements, other than as required by applicable law.
| Viemed Healthcare, INC. | ||||||
| CONDENSED CONSOLIDATED BALANCE SHEETS | ||||||
| (Expressed in thousands of U.S. Dollars, except share amounts) | ||||||
| (Unaudited) | ||||||
| At March 31, 2023 | At December 31, 2022 | |||||
| ASSETS | ||||||
| Current assets | ||||||
| Cash and cash equivalents | $ | 23,544 | $ | 16,914 | ||
| Accounts receivable, net of allowance for doubtful accounts of $11,040 and $8,483 at March 31, 2023 and December 31, 2022, respectively | 16,320 | 15,379 | ||||
| Inventory | 3,447 | 3,574 | ||||
| Income tax receivable | — | 26 | ||||
| Prepaid expenses and other assets | 3,394 | 3,849 | ||||
| Total current assets | $ | 46,705 | $ | 39,742 | ||
| Long-term assets | ||||||
| Property and equipment, net | 68,438 | 68,437 | ||||
| Equity investments | 1,994 | 2,155 | ||||
| Debt investment | 2,057 | 2,000 | ||||
| Deferred tax asset | 3,844 | 3,119 | ||||
| Other long-term assets | 1,596 | 1,590 | ||||
| Total long-term assets | $ | 77,929 | $ | 77,301 | ||
| TOTAL ASSETS | $ | 124,634 | $ | 117,043 | ||
| LIABILITIES | ||||||
| Current liabilities | ||||||
| Trade payables | $ | 4,262 | $ | 2,650 | ||
| Deferred revenue | 4,698 | 4,624 | ||||
| Income taxes payable | 1,247 | — | ||||
| Accrued liabilities | 12,817 | 11,092 | ||||
| Current portion of lease liabilities | 397 | 495 | ||||
| Total current liabilities | $ | 23,421 | $ | 18,861 | ||
| Long-term liabilities | ||||||
| Accrued liabilities | 1,010 | 889 | ||||
| Long-term lease liabilities | 162 | 199 | ||||
| Total long-term liabilities | $ | 1,172 | $ | 1,088 | ||
| TOTAL LIABILITIES | $ | 24,593 | $ | 19,949 | ||
| Commitments and Contingencies | — | — | ||||
| SHAREHOLDERS' EQUITY | ||||||
| Common stock - No par value: unlimited authorized; 38,276,389 and 38,049,739 issued and outstanding as of March 31, 2023 and December 31, 2022, respectively | 17,096 | 15,123 | ||||
| Additional paid-in capital | 12,087 | 12,125 | ||||
| Retained earnings | 70,858 | 69,846 | ||||
| TOTAL SHAREHOLDERS' EQUITY | $ | 100,041 | $ | 97,094 | ||
| TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY | $ | 124,634 | $ | 117,043 | ||
| Viemed Healthcare, INC. | |||||||
| CONDENSED CONSOLIDATED STATEMENTS OF INCOME AND COMPREHENSIVE INCOME | |||||||
| (Expressed in thousands of U.S. Dollars, except outstanding shares and per share amounts) | |||||||
| (Unaudited) | |||||||
| Three Months Ended March 31, | |||||||
| 2023 | 2022 | ||||||
| Revenue | $ | 39,556 | $ | 32,255 | |||
| Cost of revenue | 15,552 | 12,512 | |||||
| Gross profit | $ | 24,004 | $ | 19,743 | |||
| Operating expenses | |||||||
| Selling, general and administrative | 19,762 | 15,776 | |||||
| Research and development | 780 | 632 | |||||
| Stock-based compensation | 1,391 | 1,305 | |||||
| Depreciation | 240 | 237 | |||||
| Gain on disposal of property and equipment | (22 | ) | (14 | ) | |||
| Other (income) expense, net | (81 | ) | (441 | ) | |||
| Income from operations | $ | 1,934 | $ | 2,248 | |||
| Non-operating income and expenses | |||||||
| Income from equity method investments | (35 | ) | (323 | ) | |||
| Interest (income) expense, net | (49 | ) | 64 | ||||
| Net income before taxes | 2,018 | 2,507 | |||||
| Provision for income taxes | 501 | 745 | |||||
| Net income | $ | 1,517 | $ | 1,762 | |||
| Other comprehensive income | |||||||
| Change in unrealized gain/loss on derivative instruments, net of tax | — | 163 | |||||
| Other comprehensive income | $ | — | $ | 163 | |||
| Comprehensive income | $ | 1,517 | $ | 1,925 | |||
| Net income per share | |||||||
| Basic | $ | 0.04 | $ | 0.04 | |||
| Diluted | $ | 0.04 | $ | 0.04 | |||
| Weighted average number of common shares outstanding: | |||||||
| Basic | 38,156,777 | 39,621,741 | |||||
| Diluted | 40,016,693 | 40,363,456 | |||||
| Viemed Healthcare, INC. | ||||||||
| CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS | ||||||||
| (Expressed in thousands of U.S. Dollars) | ||||||||
| (Unaudited) | ||||||||
| Three Months Ended March 31, | ||||||||
| 2023 | 2022 | |||||||
| Cash flows from operating activities | ||||||||
| Net income | $ | 1,517 | $ | 1,762 | ||||
| Adjustments for: | ||||||||
| Depreciation | 4,762 | 3,397 | ||||||
| Provision for uncollectible accounts | 4,131 | 3,445 | ||||||
| Change in inventory reserve | — | (1,418 | ) | |||||
| Stock-based compensation expense | 1,391 | 1,305 | ||||||
| Distributions of earnings received from equity method investments | 196 | 221 | ||||||
| Income from equity method investments | (35 | ) | (323 | ) | ||||
| Income from debt investment | (57 | ) | — | |||||
| Gain on disposal of property and equipment | (22 | ) | (14 | ) | ||||
| Deferred income tax (benefit) expense | (725 | ) | 745 | |||||
| Net change in working capital | ||||||||
| Increase in accounts receivable | (5,072 | ) | (4,221 | ) | ||||
| Decrease in inventory | 127 | 1,372 | ||||||
| Decrease (increase) in prepaid expenses and other assets | 449 | (68 | ) | |||||
| Increase (decrease) in trade payables | 641 | (467 | ) | |||||
| Increase in deferred revenue | 74 | 135 | ||||||
| Increase in accrued liabilities | 1,846 | 58 | ||||||
| Change in income tax payable/receivable | 1,273 | 1,217 | ||||||
| Net cash provided by operating activities | $ | 10,496 | $ | 7,146 | ||||
| Cash flows from investing activities | ||||||||
| Purchase of property and equipment | (4,681 | ) | (3,963 | ) | ||||
| Investment in equity investments | — | (100 | ) | |||||
| Proceeds from sale of property and equipment | 776 | 256 | ||||||
| Net cash used in investing activities | $ | (3,905 | ) | $ | (3,807 | ) | ||
| Cash flows from financing activities | ||||||||
| Proceeds from exercise of options | 544 | — | ||||||
| Principal payments on notes payable | — | (39 | ) | |||||
| Principal payments on term note | — | (433 | ) | |||||
| Shares repurchased under the share repurchase program | — | (1,887 | ) | |||||
| Shares redeemed to pay income tax | (505 | ) | (119 | ) | ||||
| Repayments of lease liabilities | — | (21 | ) | |||||
| Net cash provided by (used in) financing activities | $ | 39 | $ | (2,499 | ) | |||
| Net increase in cash and cash equivalents | 6,630 | 840 | ||||||
| Cash and cash equivalents at beginning of year | 16,914 | 28,408 | ||||||
| Cash and cash equivalents at end of period | $ | 23,544 | $ | 29,248 | ||||
| Supplemental disclosures of cash flow information | ||||||||
| Cash paid during the period for interest | $ | 42 | $ | 66 | ||||
| Cash (received) paid during the period for income taxes, net of refunds | $ | (40 | ) | $ | 1,217 | |||
Non-GAAP Financial Measures
This press release refers to "Adjusted EBITDA", which is a financial measure that is not prepared in accordance with generally accepted accounting principles in the United States ("GAAP"). Management believes Adjusted EBITDA provides helpful information with respect to the Company's operating performance as viewed by management, including a view of the Company's business that is not dependent on the impact of the Company's capitalization structure and items that are not part of the Company's day-to-day operations. Management uses Adjusted EBITDA (i) to compare the Company's operating performance on a consistent basis, (ii) to calculate incentive compensation for the Company's employees, (iii) for planning purposes, including the preparation of the Company's internal annual operating budget, and (iv) to evaluate the performance and effectiveness of the Company's operational strategies. Accordingly, management believes that Adjusted EBITDA provides useful information in understanding and evaluating the Company's operating performance in the same manner as management. In calculating Adjusted EBITDA, certain items (mostly non-cash) are excluded from net income including interest, taxes, stock based compensation, and depreciation of property and equipment. Beginning with financial results reported for periods in fiscal year 2023, Adjusted EBITDA also excludes transaction costs and expenses related to acquisition and integration efforts associated with recently announced or completed acquisitions. This modification enables investors to compare period-over-period results on a more consistent basis without the effects of acquisitions. We have recast Adjusted EBITDA for prior periods when reported to conform to the modified presentation.
The following table is a reconciliation of net income (loss), the most directly comparable U.S. GAAP measure, to Adjusted EBITDA, on a historical basis for the periods indicated:
| Viemed Healthcare, INC. | |||||||||||||||||
| Reconciliation of Net Income to Non-GAAP Adjusted EBITDA | |||||||||||||||||
| (Expressed in thousands of U.S. Dollars) | |||||||||||||||||
| (Unaudited) | |||||||||||||||||
| For the quarter ended | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | |||||||||
| Net Income | $ | 1,517 | $ | 2,438 | $ | 1,055 | $ | 967 | $ | 1,762 | $ | 4,087 | $ | 1,789 | $ | 1,566 | |
| Add back: | |||||||||||||||||
| Depreciation | 4,762 | 4,373 | 4,120 | 3,740 | 3,397 | 3,120 | 2,867 | 2,716 | |||||||||
| Interest (income) expense | (49 | ) | 32 | 42 | 59 | 64 | 69 | 75 | 83 | ||||||||
| Stock-based compensation (a) | 1,391 | 1,317 | 1,309 | 1,271 | 1,305 | 1,305 | 1,302 | 1,236 | |||||||||
| Transaction costs (b) | 206 | — | — | — | — | — | — | — | |||||||||
| Income tax expense | 501 | 1,146 | 456 | 421 | 745 | 968 | 1,386 | 1,246 | |||||||||
| Adjusted EBITDA | $ | 8,328 | $ | 9,306 | $ | 6,982 | $ | 6,458 | $ | 7,273 | $ | 9,549 | $ | 7,419 | $ | 6,847 | |
(a) Represents non-cash, equity-based compensation expense associated with option and RSU awards.
(b) Represents transaction costs and expenses related to acquisition and integration efforts associated with recently announced or completed acquisitions.
Use of Non-GAAP Financial Measures
Adjusted EBITDA should be considered in addition to, not as a substitute for, or superior to, financial measures calculated in accordance with U.S. GAAP. It is not a measurement of the Company's financial performance under U.S. GAAP and should not be considered as an alternative to revenue or net income, as applicable, or any other performance measures derived in accordance with U.S. GAAP and may not be comparable to other similarly titled measures of other companies or businesses. Adjusted EBITDA has limitations as an analytical tool and you should not consider it in isolation or as a substitute for analysis of the Company's operating results as reported under U.S. GAAP. Adjusted EBITDA does not reflect the impact of certain cash charges resulting from matters the Company considers not to be indicative of ongoing operations; and other companies in the Company's industry may calculate Adjusted EBITDA differently than we do, limiting its usefulness as a comparative measure.
| Viemed Healthcare, INC. | ||||||||||||||||||||||||
| Key Financial and Operational Information | ||||||||||||||||||||||||
| (Expressed in thousands of U.S. Dollars, except vent patients) | ||||||||||||||||||||||||
| (Unaudited) | ||||||||||||||||||||||||
| For the quarter ended | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | ||||||||||||||||
| Financial Information: | ||||||||||||||||||||||||
| Revenue | $ | 39,556 | $ | 37,508 | $ | 35,759 | $ | 33,310 | $ | 32,255 | $ | 31,962 | $ | 29,285 | $ | 27,399 | ||||||||
| Gross Profit | $ | 24,004 | $ | 22,896 | $ | 21,651 | $ | 20,390 | $ | 19,743 | $ | 19,662 | $ | 18,381 | $ | 17,625 | ||||||||
| Gross Profit % | 61 | % | 61 | % | 61 | % | 61 | % | 61 | % | 62 | % | 63 | % | 64 | % | ||||||||
| Net Income | $ | 1,517 | $ | 2,438 | $ | 1,055 | $ | 967 | $ | 1,762 | $ | 4,087 | $ | 1,789 | $ | 1,566 | ||||||||
| Cash (As of) | $ | 23,544 | $ | 16,914 | $ | 21,478 | $ | 21,922 | $ | 29,248 | $ | 28,408 | $ | 26,867 | $ | 31,151 | ||||||||
| Total Assets (As of) | $ | 124,634 | $ | 117,043 | $ | 119,419 | $ | 115,904 | $ | 119,007 | $ | 117,962 | $ | 115,486 | $ | 111,014 | ||||||||
| Adjusted EBITDA (1) | $ | 8,328 | $ | 9,306 | $ | 6,982 | $ | 6,458 | $ | 7,273 | $ | 9,549 | $ | 7,419 | $ | 6,847 | ||||||||
| Operational Information: | ||||||||||||||||||||||||
| Vent Patients (2) | 9,337 | 9,306 | 9,127 | 8,837 | 8,434 | 8,405 | 8,200 | 8,103 | ||||||||||||||||
(1) Refer to "Non-GAAP Financial Measures" section above for definition of Adjusted EBITDA.
(2) Vent Patients represents the number of active ventilator patients on recurring billing service at the end of each calendar quarter.
Figure one: Individual patient (001-005) and pooled results highlighting improvements in fibromyalgia domains as presented by University of Michigan 9 August 2024 (adapted)
Figure two: Individual patient and pooled results as presented by University of Michigan 9 August 2024 (adapted)